v3.25.2
Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2021
USD ($)
item
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Agreements            
Payments of consideration under RPAs, AAAs and CPPAs       $ 8,000 $ 37,000  
Long-term royalty and commercial payment receivables under the cost recovery method   $ 58,937   58,937   $ 55,936
Trade and other receivables, net   1,817   1,817   1,839
Income from purchased receivables under cost recovery method   1,743 $ 870 7,268 870  
Viracta | Royalty Purchase Agreement            
Agreements            
Number of drug candidates | item 2          
Payments of consideration under RPAs, AAAs and CPPAs $ 13,500          
Maximum amount of potential milestones, potential royalties on sales and other payments receivable 54,000          
Amount of maximum consideration retained 5,000          
Maximum amount of potential regulatory and commercial milestones receivable 57,000          
Long-term royalty and commercial payment receivables under the cost recovery method $ 13,500          
Trade and other receivables, net   1,700   1,700   $ 1,300
Income from purchased receivables under cost recovery method   $ 1,700 $ 900 $ 7,200 $ 900